Best of BS Opinion: Related party risks, a new green wave of growth & more
Here are the best of Business Standard's opinion pieces for Wednesday
)
premium
Illustration: Binay Sinha
The controversy over Bharat Biotech’s Covaxin deal with the Brazilian government centres on, among other things, payments to offshore “marketing agency”. Though the deal came to nothing, the practice of promoters routing related-party transactions through offshore shell companies can hardly be construed as good corporate governance. Though tax laws may close such loopholes, the responsibility lies with corporate boards to monitor such transactions, the top edit argues here